Clinical Trial Update: Gimatecan in Treating Patients With Recurrent or Progressive Primary Malignant Glioma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial results are reported for gimatecan in patients with recurrent or progressive primary malignant glioma. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Glioma

Drugs mentioned

• gimatecan (gimatecan)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Brain and Central Nervous System Tumors | Phase 1, Phase 2 | Status: COMPLETED